Elixir: Elixir Medical has positive data for drug-eluting bioadaptive implant

Elixir Medical announced positive data demonstrating the benefit of its DynamX coronary bioadaptor system in target lesion failure (TLF). Data highlighted the success of DynamX compared to Medtronic's Resolute Onyx zotarolimus drug-eluting stent (DES). The study looked at complex patient populations within the INFINITY-SWEDEHEART randomized controlled trial. Data included an analysis of patients with acute [...]The post Elixir Medical has positive data for drug-eluting bioadaptive implant appeared first on Drug Delivery Business.